KRAS and cancer: We next investigated the effect of PTPN2 on cancer cell growth, using pooled siRNAs to knockdown PTPN2 in a panel of five mutant KRAS-harboring human cancer cell lines (H460, PaTu8988T, HCT-116, A549, and DLD-1) and two KRAS wildtype human cancer cell lines (HT-1080 and SK-MEL-30).